Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets

Haemonetics Corporation stocks have been trading up by 17.1 percent following strong earnings momentum and bullish analyst upgrades.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading HAE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

Q1 adjusted EPS came in at $1.14, crushing the $0.87 Wall Street estimate and signaling stronger earnings power for HAE.
Net revenue reached $339.4M versus the $327.9M consensus, showing broad-based demand across Haemonetics’ businesses.
Management nudged FY27 revenue and EPS growth guidance up to 5%–8%, reinforcing confidence in multi-year execution.
Bank of America lifted its HAE price target to $100 and reiterated a Buy rating after meetings with the CEO.
Raymond James pushed its HAE target to $105 and kept an Outperform rating, underscoring confidence in further upside.

Quick Financial Overview

HAE has quietly turned into a momentum story backed by real numbers. In fiscal Q1 2027, Haemonetics posted $339.4M in revenue, topping the $327.9M consensus. Adjusted EPS landed at $1.14 versus the $0.87 estimate. That is not a small beat — it shows operating leverage kicking in as scale builds.

On the chart, HAE has broken out. From 2026/07/24 around the high-$70s to the recent close near $105.71 on 2026/08/18, the stock has trended higher almost every week. That is a serious uptrend for active trading. Intraday, the 5‑minute tape shows tight action between roughly $104 and $106 for most of the afternoon session, telling traders that HAE is consolidating gains rather than immediately giving them back.

More Breaking News

Fundamentally, Haemonetics sports roughly 59% gross margins and a profit margin a bit above 7%. The P/E near the mid‑40s says the market already pays up for this growth story. Debt is manageable, with interest coverage over 20x and solid free cash flow of about $44.4M in the latest quarter. For traders, that combination of trend, beats, and balance sheet strength keeps HAE on breakout watch.

Why Traders Are Watching HAE Right Now

The real catalyst for Haemonetics was the fiscal Q1 print. HAE beat on both the top and bottom line, gained share in Plasma, sustained momentum in Blood Management Technologies, and got Interventional Technologies back to growth. That is not a narrow story pinned to one product. It is a diversified growth setup that trend traders love to see.

HAE then layered on a guidance raise. Management bumped its FY27 revenue and adjusted EPS growth outlook to 5%–8%, up from 4%–7%. The move was modest, but it matters. It tells the market Haemonetics is comfortable putting higher numbers out there several years ahead. When a company with a P/E in the 40s confirms the growth path, traders often stay interested, even after a strong run.

Wall Street’s response has been loud. Bank of America lifted its HAE target from $93 to $100 and stuck with a Buy call after hosting the CEO at a SMID‑cap conference. Raymond James went even higher, taking its target to $105 and reiterating Outperform. Baird raised its target to $96, also with an Outperform, after calling out the “larger‑than‑expected” Q1 beat and guidance hike.

Barrington Research pushed its HAE target to $95, citing improving profitability and the potential to cut debt by fiscal 2027. Even Citi, which stayed Neutral, raised its target to $92. Across the board, analysts are recalibrating their models. Consensus now sits around $96.90, while BofA sits at $100. For short‑term traders, that cluster of higher price targets can act as fuel, especially when HAE pulls back toward support and then turns back up.

Conclusion

For active traders, Haemonetics sits in an interesting spot. HAE has a strong fundamental story — earnings and revenue beats, a multi‑segment growth engine, rising FY27 guidance, and expanding free cash flow. At the same time, the stock is extended after running from the high‑$70s to above $100 in a few weeks. That is where discipline matters. Breakout names like HAE can keep running, but they can also snap back hard when the crowd gets complacent.

The intraday action shows HAE digesting gains in a tight band, with buyers stepping in on dips around the low‑$100s. Analysts from Bank of America, Raymond James, Baird, Barrington, and others are all leaning bullish, with targets mostly in the mid‑$90s to low‑$100s range and commentary focused on upside potential, margin expansion, and future debt reduction. Citi’s Neutral stance adds just enough skepticism to keep traders honest on valuation risk. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” That’s a useful lens for evaluating whether HAE’s current price action truly aligns with a high‑probability trading setup.

This is exactly the kind of setup Tim Sykes talks about when he says, “The market rewards preparation, not prediction — study the pattern, wait for the setup, and always be ready to cut losses fast.” For HAE, that means tracking the chart, respecting key support levels, and letting the price action confirm whether the next move is another leg higher or a sharp shakeout. As always, this analysis is for educational and research purposes only, not advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!